We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Mediclinic International Plc | LSE:MDC | London | Ordinary Share | GB00B8HX8Z88 | ORD 10P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 501.00 | 0.00 | 01:00:00 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| 0 | 0 | N/A | 0 |
From Apr 2019 to Apr 2024
TIDMMDC
RNS Number : 8190T
Mediclinic International plc
23 July 2020
Mediclinic International plc
(Incorporated in England and Wales)
Company Number: 08338604
LSE Share Code: MDC
JSE Share Code: MEI
NSX Share Code: MEP
ISIN: GB00B8HX8Z88
LEI: 2138002S5BSBIZTD5I60
("Mediclinic" , or the " Company ", or the "Group" )
23 July 2020
ANNOUNCEMENT OF THE ANNUAL GENERAL MEETING POLL RESULTS
Mediclinic announces that at its Annual General Meeting ("AGM"), held on 22 July 2020 in accordance with the arrangements set out in the Notice of AGM (the "Notice"), all resolutions set out in the Notice were passed by the requisite majority of votes by shareholders by way of poll. The results of the poll for each resolution are set out below.
Results of poll
Hot Features
Premium
Total % of Votes % Votes % Votes
Shares Issued For(1) Against Withheld(2)
Voted Share
Capital
Voted(3)
Ordinary
Resolutions
------------------------ -------- ---------- -------- ------- --------- ------ -------------
To receive
the Company's
financial
statements
and the reports
of the directors 651 029 650 973
1. and auditor 501 88.31 436 99.99 56 065 0.01 765 665
------------------------ -------- ---------- -------- ------- --------- ------ -------------
To approve
the Directors'
Remuneration 649 411 644 127 5 283 2 384
2. Report 121 88.09 734 99.19 387 0.81 045
------------------------ -------- ---------- -------- ------- --------- ------ -------------
To approve
the Directors'
Remuneration 651 380 633 886 17 494
3. Policy 968 88.35 281 97.31 687 2.69 414 198
------------------------ -------- ---------- -------- ------- --------- ------ -------------
To elect Dame
Inga Beale 651 404 651 387
4. as a director 426 88.36 915 100.00 16 511 0.00 390 741
------------------------ -------- ---------- -------- ------- --------- ------ -------------
To elect Mr
Tom Singer 651 404 650 720
5. as a director 426 88.36 860 99.90 683 566 0.10 390 741
------------------------ -------- ---------- -------- ------- --------- ------ -------------
To re-elect
Dr Ronnie
van der Merwe 651 409 650 544
6. as a director 511 88.36 510 99.87 865 001 0.13 385 656
------------------------ -------- ---------- -------- ------- --------- ------ -------------
To re-elect
Mr Jurgens
Myburgh as 651 405 650 346 1 058
7. a director 217 88.36 872 99.84 345 0.16 389 950
------------------------ -------- ---------- -------- ------- --------- ------ -------------
To re-elect
Mr Alan Grieve 651 405 650 718
8. as a director 241 88.36 418 99.89 686 823 0.11 389 926
------------------------ -------- ---------- -------- ------- --------- ------ -------------
To re-elect
Dr Muhadditha
Al Hashimi 651 408 650 760
9. as a director 721 88.36 951 99.90 647 770 0.10 386 446
------------------------ -------- ---------- -------- ------- --------- ------ -------------
To re-elect
Mr Jannie
Durand as 651 405 615 278 36 127
10. a director 784 88.36 225 94.45 559 5.55 389 383
------------------------ -------- ---------- -------- ------- --------- ------ -------------
To re-elect
Dr Felicity
Harvey as 651 405 650 754
11. a director 217 88.36 844 99.90 650 373 0.10 389 950
------------------------ -------- ---------- -------- ------- --------- ------ -------------
To re-elect
Mr Danie Meintjes 651 405 642 412 8 993
12. as a director 661 88.36 072 98.62 589 1.38 389 506
------------------------ -------- ---------- -------- ------- --------- ------ -------------
To re-elect
Dr Anja Oswald 651 409 650 761
13. as a director 091 88.36 951 99.90 647 140 0.10 386 076
------------------------ -------- ---------- -------- ------- --------- ------ -------------
To re-elect
Mr Trevor
Petersen as 651 409 642 489 8 919
14. a director 090 88.36 636 98.63 454 1.37 386 076
------------------------ -------- ---------- -------- ------- --------- ------ -------------
To re-appoint
PricewaterhouseCoopers
LLP as auditor 651 405 648 862 2 542
15. of the Company 420 88.36 581 99.61 839 0.39 389 747
------------------------ -------- ---------- -------- ------- --------- ------ -------------
To authorise
the Audit
and Risk Committee
to determine
the remuneration 651 405 651 393
16. of the auditor 369 88.36 310 100.00 12 059 0.00 389 798
------------------------ -------- ---------- -------- ------- --------- ------ -------------
To authorise
the directors
to make political 651 424 544 059 107 364
17. donations 227 88.36 407 83.52 820 16.48 370 940
------------------------ -------- ---------- -------- ------- --------- ------ -------------
To authorise
the directors
to allot ordinary 651 422 518 848 132 573
18. shares 134 88.36 733 79.65 401 20.35 373 033
------------------------ -------- ---------- -------- ------- --------- ------ -------------
Special Resolutions
------------------------ -------- ---------- -------- ------- --------- ------ -------------
To authorise
the directors
to dis-apply
statutory
pre-emption 651 402 535 602 115 800
19. rights 291 88.36 120 82.22 171 17.78 392 876
------------------------ -------- ---------- -------- ------- --------- ------ -------------
To authorise
the directors
to dis-apply
pre-emption
rights for
purposes of
acquisitions
or capital 651 402 551 523 99 878
20. investments 432 88.36 823 84.67 609 15.33 392 734
------------------------ -------- ---------- -------- ------- --------- ------ -------------
To approve
the calling
of general
meetings on
not less than
14 days' clear
notice (other 651 420 607 406 44 014
21. than AGMs) 376 88.36 150 93.24 226 6.76 374 791
------------------------ -------- ---------- -------- ------- --------- ------ -------------
To adopt the
new Articles
of Association 651 382 651 229
22. of the Company 529 88.35 816 99.98 152 713 0.02 412 638
------------------------ -------- ---------- -------- ------- --------- ------ -------------
Votes of shareholders excluding the controlling shareholder, Remgro Limited(4) , on the election and re-election of independent non-executive directors
Ordinary Total % of Votes % Votes % Votes
Resolutions Shares Issued For(1) Against Withheld(2)
Voted Share
Capital
Voted(3)
To elect Dame
Inga Beale 322 906 322 890
4. as a director 538 79.00 027 99.99 16 511 0.01 390 741
---------------- -------- ---------- -------- ------ --------- ----- -------------
To elect Mr
Tom Singer 322 906 322 222
5. as a director 538 79.00 972 99.79 683 566 0.21 390 741
---------------- -------- ---------- -------- ------ --------- ----- -------------
To re-elect
Mr Alan Grieve 322 907 322 220
8. as a director 353 79.00 530 99.79 686 823 0.21 389 926
---------------- -------- ---------- -------- ------ --------- ----- -------------
To re-elect
Dr Muhadditha
Al Hashimi 322 910 322 263
9. as a director 833 79.00 063 99.80 647 770 0.20 386 446
---------------- -------- ---------- -------- ------ --------- ----- -------------
To re-elect
Dr Felicity
Harvey as 322 907 322 256
11. a director 329 79.00 956 99.80 650 373 0.20 389 950
---------------- -------- ---------- -------- ------ --------- ----- -------------
To re-elect
Dr Anja Oswald 322 911 322 264
13. as a director 203 79.00 063 99.80 647 140 0.20 386 076
---------------- -------- ---------- -------- ------ --------- ----- -------------
To re-elect
Mr Trevor
Petersen as 322 911 313 991 8 919
14. a director 202 79.00 748 97.24 454 2.76 386 076
---------------- -------- ---------- -------- ------ --------- ----- -------------
Notes:
1. Any proxy appointments giving discretion to the Chair
of the AGM have been included in the "For" total.
2. A vote "Withheld" is not a vote in law and is not counted
in the calculation of the votes "For" or "Against" a resolution.
3. The Company's total ordinary shares in issue (total voting
rights) as at 22 July 2020 was 737 243 810 ordinary shares
of 10 pence each. Ordinary shareholders are entitled to
one vote per ordinary share held. In the table showing
votes of shareholders on the election and re-election
of independent non-executive directors, the percentage
of issued capital voted has been calculated excluding
the shares of the controlling shareholder, Remgro Limited.
4. As the Company has a controlling shareholder, Remgro Limited,
as defined in the Financial Conduct Authority's Listing
Rules, each resolution to elect an independent non-executive
director (Resolutions 4, 5, 8, 9, 11, 13 and 14) have
under Listing Rule 9.2.2E been approved by a majority
of the votes cast by:
(a) the shareholders of the Company as a whole; and
(b) the independent shareholders of the Company, that
is, all the shareholders entitled to vote on each resolution,
excluding the controlling shareholder.
Statement regarding voting results
The Board notes that while Resolution 18 was passed with a majority of 79.65%, a number of our shareholders opposed that resolution. The Board notes that the voting outcome reflects the differing market practice between the United Kingdom ("UK") and South Africa, where shareholders in the latter jurisdiction usually approve more restricted levels of authority to issue shares and prefer to vote on the proposed allotments of shares on a case-by-case basis. The Company has consulted regularly with its larger international shareholders on this matter. Many operate under policies that do not permit the UK standard level of authority to be supported, although a number do understand the Company's position. As Mediclinic is a UK premium-listed company, the Board considers it appropriate to seek authorities in line with the UK's Investment Association's Share Capital Management Guidelines to: (a) allow the Company to respond to market developments; and (b) enable allotments to take place to finance business opportunities as they arise. The views of all shareholders are important to Mediclinic and the Board will continue to engage with international shareholders on this topic and will publish an update on shareholder engagement within six months of the AGM, as required by the UK Corporate Governance Code. However, as the voting outcome reflects the difficulty in balancing the expectations of different markets, it is likely that there will continue to be significant votes against this resolution.
A copy of the special resolutions and certain ordinary resolutions affecting the Company's constitution which were passed at the meeting will shortly be submitted to the National Storage Mechanism in accordance with paragraph 9.6.2 of the Listing Rules. In addition, the Company will submit to the National Storage Mechanism a copy of its Articles of Association dated 22 July 2020 in accordance with paragraph 9.2.6E of the Listing Rules. These documents will be available for inspection at https://data.fca.org.uk/#/nsm/nationalstoragemechanism .
About Mediclinic International plc
Mediclinic is a diversified international private healthcare services group, established in South Africa in 1983, with divisions in Switzerland, Southern Africa (South Africa and Namibia) and the United Arab Emirates ("UAE").
The Group's core purpose is to enhance the quality of life.
Its vision is to be the partner of choice that people trust for all their healthcare needs.
Mediclinic is focused on providing specialist-orientated, multi-disciplinary services across the continuum of care in such a way that the Group will be regarded as the most respected and trusted provider of healthcare services by patients, medical practitioners, funders and regulators of healthcare in each of its markets.
At 1 July 2020, Mediclinic comprised 76 hospitals, eight sub-acute and specialised hospitals, 15 day case clinics and 18 outpatient clinics. Hirslanden operated 17 hospitals and three day case clinics in Switzerland with more than 1 800 inpatient beds; Mediclinic Southern Africa operations included 52 hospitals (three of which in Namibia), eight sub-acute and specialised hospitals and 10 day case clinics (four of which operated by Intercare) across South Africa, and more than 8 700 inpatient beds; and Mediclinic Middle East operated seven hospitals, two day case clinics and 18 outpatient clinics with more than 900 inpatient beds in the UAE.
The Company's primary listing is on the London Stock Exchange ("LSE") in the UK, with secondary listings on the JSE Ltd in South Africa and the Namibian Stock Exchange in Namibia.
Mediclinic also holds a 29.9% interest in Spire Healthcare Group plc, a leading private healthcare group based in the UK and listed on the LSE.
For further information, please contact:
Company Secretary, Link Company Matters Limited
Caroline Emmet
+44 (0)20 7954 9548
Investor Relations, Mediclinic International plc
James Arnold, Head of Investor Relations
ir@mediclinic.com
+44 (0)20 3786 8181
Media queries
FTI Consulting
Ben Atwell/Ciara Martin - UK
+44 (0)20 3727 1000
Sherryn Schooling - South Africa
+27 (0)21 487 9000
Registered address: 6(th) Floor, 65 Gresham Street, London, EC2V 7NQ, United Kingdom
Website: www.mediclinic.com
Corporate broker (UK): Morgan Stanley & Co International plc and UBS Investment Bank
JSE sponsor (South Africa): Rand Merchant Bank (A division of FirstRand Bank Limited)
NSX sponsor (Namibia): Simonis Storm Securities (Pty) Ltd
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
END
RAGSEFFUEESSEIW
(END) Dow Jones Newswires
July 23, 2020 02:00 ET (06:00 GMT)
1 Year Mediclinic Chart |
1 Month Mediclinic Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
